SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community debate, driven by a recent Google research paper highlighting its quantum-resistant technology and ongoing institutional adoption discussions. While some investors remain highly bullish on its long-term potential and infrastructure utility, others are actively criticizing its price performance and expressing skepticism regarding a significant recovery.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven meme token that is actively engaging holders through manual airdrops and a high-energy, "no-roadmap" approach to growth. Investors are discussing the coin's low market cap, its potential for weekend volatility, and the community's push to drive volume and increase visibility across social platforms.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh significant clinical catalysts, including upcoming Phase 3 data and potential FDA updates, against a high level of short interest that has fueled aggressive community debate over a possible short squeeze. While some traders are focused on the stock's volatility and the prospect of a major rebound, others remain cautious, debating the long-term impact of recent capital raises and the broader outlook for the gene-editing sector.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in investor interest and trading volume as the community speculates on its role within the ApeChain ecosystem and potential short-squeeze conditions. Many traders are actively discussing the token's price action and volatility, drawing comparisons to past market cycles while debating whether it remains a strong candidate for future momentum.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is capturing investor attention as the AI industry faces significant volatility, with participants actively debating the impact of recent security breaches at competitor firms and the company's long-term potential in data training for defense and robotics. Discussions center on technical chart patterns, the stock's role in the AI supply chain, and whether recent consolidation signals a future breakout or further downside.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following a significant capital raise through a $550 million convertible note offering, which has sparked mixed reactions as investors weigh the company's long-term liquidity against concerns over dilution and recent insider selling. The community remains heavily focused on the commercial ramp of Casgevy, the potential for future M&A activity, and ongoing clinical pipeline readouts expected throughout the year.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. is currently in the spotlight as investors react to reports of a binding multi-billion dollar acquisition offer from Sun Pharmaceutical Industries, fueling intense debate regarding the deal's valuation versus the company's significant debt load. Community discussion is focused on the viability of the buyout, potential competing bids from other firms, and the divergence between market pricing and the rumored acquisition price.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust is trending as institutional interest remains strong, with community members actively discussing a potential breakout toward new highs amidst broader market optimism. Analysts and traders are debating whether current price action signals a lasting bull market or a consolidation phase, keeping investor focus locked on the fund's role as a primary vehicle for crypto exposure.

Polygon

Polygon is currently drawing intense community focus as traders debate its long-term potential, weighing high network activity against recent price stagnation and shifts in platform utilization. While some investors are aggressively accumulating, citing the network's role in stablecoin volume and emerging payment infrastructure as reasons for a potential reversal, others remain skeptical about the token's ability to decouple from bearish sentiment.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg is seeing intense community focus due to a combination of extremely low float dynamics and consistent insider buying, which many traders believe has created a structural setup for a significant short squeeze. The community is actively scrutinizing institutional short interest and trading data, viewing recent price volatility as an attempt by market makers to flush out retail positions before a potential major move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

Should You Invest in the VanEck Biotech ETF (BBH)?

<ul class="summary-bullets"><li>Arrow Aviation provides private flights to the public sector, with specialized operations such as air ambulances.</li><li>The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation.</li><li>The MoU also grants options to acquire the remaining 49% after two years, Polyrizon said.</li></ul>Shares of Polyrizon (PLRZ) gained 6% in premarket trading on Tuesday after the company announced that it recently signed a memorandum of understanding to acquire a 51% stake in global private aviation firm Arrow Aviation through a cash investment of NIS 18 million ($5.8 million).“We believe that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing us to leverage our strong financial position to enter the dynamic private aviation market, a market set to grow to $41.38 billion by 2030, through a potential acquisition of a high-growth, high-potential company,” said Tomer Izraeli, CEO of Polyrizon.<h2 class="st-heading-2">Deal Rationale</h2>Arrow Aviation provides private flights to the public sector, with specialized operations including air ambulances, medical evacuations, rescue missions, special-needs transport, medical tourism, and cargo services, including the transport of sensitive and hazardous materials under special licenses.The company last reported annual unaudited revenues of around $19 million and adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of around $3 million.The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation in exchange for a convertible note issued by Polyrizon.&nbsp;Arrow Aviation shareholders will also forgive outstanding debts for convertible notes, allowing the company to operate debt-free after closing. The MoU grants options to acquire the remaining 49% after two years, with a definitive agreement expected within 30 days, subject to due diligence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits turned 'neutral' from 'bullish' a day earlier.One user noted the increasing volumes traded and the company's market cap.<stembedurl>https://stocktwits.com/raulaa/message/644568154</stembedurl><a href="https://stocktwits.com/symbol/PLRZ">PLRZ shares</a> have gained more than 66% so far this year.$1 = NIS 3.1For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business?

The company announced that it recently signed an MoU to acquire a 51% stake in private aviation firm Arrow Aviation for around $5.8 million.

Equity

<ul class="summary-bullets"><li>Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74.</li><li>Sales of the Eylea declined amid competitive pressure and a shift of patients to the high-dose version.</li><li>Sanofi collaboration revenue rose 35% as the company received a larger share of profits from jointly commercialized antibody drugs.</li></ul>Regeneron Pharmaceuticals (REGN) reported a better-than-expected fourth-quarter (Q4) print, as higher sales from its collaboration with&nbsp;Sanofi and Eylea HD injections offset lower revenue from Eylea, which is&nbsp;marketed outside the U.S. by Bayer.Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74.<a href="https://stocktwits.com/symbol/REGN">REGN shares</a>&nbsp;were 2.6% lower in pre-market trading on Friday, while retail sentiment on Stocktwits remained ‘neutral’ over the past 24 hours.<h2 class="st-heading-2">Revenue Breakdown</h2>Eylea HD sales climbed 66% in the fourth quarter as strong demand lifted volumes, though gains were partly offset by lower pricing. In contrast, sales of the Eylea declined 52% amid competitive pressure, a shift of patients to the high-dose version, and affordability-driven use of cheaper alternatives, the company said.Eylea is a prescription medicine injected into the eye to treat conditions like Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME). Eylea HD is a higher-dose and longer-lasting version of Eylea.Sanofi collaboration revenue rose 35% as the company received a larger share of profits from jointly commercialized antibody drugs, driven primarily by stronger sales of Dupixent, used to treat eczema.“In the fourth quarter, we secured label expansions and new filler solutions for EYLEA HD, further enhancing its commercial potential. Dupixent received new approvals in Japan and Europe and is currently the most widely used innovative branded antibody medicine, with over 1.4 million active patients worldwide,” said Leonard S. Schleifer, President and CEO of Regeneron.The company also forecast non-GAAP R&amp;D costs of $5.90-$6.10 billion for full-year 2026, significantly higher than $5.15 billion in FY2025. The company has around 45 product candidates in clinical development, it added.<h2 class="st-heading-2">Stock Watch</h2>On Thursday, TD Cowen raised its price target on Regeneron to $820 from $800 and maintained a ‘Buy’ rating. This implies a&nbsp;12%&nbsp;upside&nbsp;from the current trading price.The stock has gained 9.2% over the past year, but is down 3.2% year to date.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/silver-sees-sharp-decline-as-dollar-gains/cmyS0BER4Sb"> Silver Plummets 18% After Weeks Of Relentless Rally – AG, HL, PAAS Stocks Also Dragged Lower&nbsp;</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock 

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

A High-Dose Bet Is Paying Off For Regeneron, But Core Eylea Weakness Caps Upside

VanEck Announces Year-End Distributions for VanEck Equity ETFs

VanEck announced today the following 2025 annual distributions per share for its VanEck equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22...

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

BBH
VanEck Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BBH News

BBHVanEck Biotech ETF